NCT02402920 2026-03-10
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
10 trialsNCT03290079 2025-12-22
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03910660 2025-10-20
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT02973997 2025-08-29
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
Phase 2 Completed
NCT03012620 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT04373265 2024-02-23
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Corcept Therapeutics
Phase 1 Completed
NCT03043664 2023-06-29
PLANET
Duke University
Phase 1/2 Completed
NCT02688608 2022-02-10
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Completed
NCT02939651 2021-03-09
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Completed
NCT03211117 2020-03-25
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
Mayo Clinic
Phase 2 Completed